Cetuximab as First-line Treatment for Metastatic Colorectal Cancer: Caution With Interpretation of Cost-Effectiveness Results Toward Medical Decision Making

被引：0

作者：

Franken, Mira D. ^{[1
]}

Koopman, Miriam ^{[1
]}

van Oijen, Martijn G. H. ^{[2
]}

机构：

[1] Univ Med Ctr Utrecht, Dept Med Oncol, Utrecht, Netherlands

[2] Univ Amsterdam, Acad Med Ctr, Dept Med Oncol, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands

来源：

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS | 2016年 / 39卷 / 02期

关键词：

D O I：

10.1097/COC.0000000000000253

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：214 / 214

页数：1

共 50 条

[21] Cost-effectiveness of FOLFIRINOX for first-line treatment of metastatic pancreatic cancer.
Attard, Cheryl L.
Brown, Stephen
Alloul, Karine
Moore, Malcolm J.
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
[22] Cetuximab and bevacizumab in addition to chemotherapy first-line for left-side metastatic colorectal cancer: A cost-effectiveness analysis.
Zhang, Yanqiao
Zheng, Tongsen
Liu, Maobai
Li, Te
Wu, Bin
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
[23] COST EFFECTIVENESS OF CETUXIMAB IN FIRST LINE TREATMENT OF METASTATIC COLORECTAL CANCER: A MODELLING APPROACH FOR THE UK
Garrell, D.
Griebsch, I
Samyshkin, Y.
VALUE IN HEALTH, 2008, 11 (06) : A465 - A465
[24] COST EFFECTIVENESS OF CETUXIMAB IN FIRST LINE TREATMENT OF METASTATIC COLORECTAL CANCER: DESCRIPTION OF A NICE SUBMISSION
Eggington, S. G.
Garrell, D.
Griebsch, I
Samyshkin, Y.
VALUE IN HEALTH, 2009, 12 (07) : A279 - A279
[25] Cost-Effectiveness of Cetuximab and Bevacizumab in the First-Line Treatment of Metastatic Colorectal Cancer (mCRC) for Patients With KRas Wild-Type Tumours in the United Kingdom
Samyshkin, Y.
Hertel, N.
Griebsch, I.
EUROPEAN JOURNAL OF CANCER, 2011, 47 : S264 - S264
[26] COST-EFFECTIVENESS OF CETUXIMAB AND BEVACIZUMAB IN THE FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER (MCRC) FOR PATIENTS WITH KRAS WILD-TYPE TUMOURS IN THE UNITED KINGDOM
Samyshkin, Y.
Hertel, N.
Griebsch, I
VALUE IN HEALTH, 2011, 14 (07) : A446 - A447
[27] A Cost-effectiveness Analysis of Adding Cetuximab to the First-line Treatment of Metastatic Colorectal Carcinoma in Iran; Considering Genetic Screening for Precision Medicine
Nazila Yousefi
Alireza Salimi
Ghader Mohammadnezhad
Saeed Taheri
Farzad Peiravian
Journal of Gastrointestinal Cancer, 2023, 54 : 1212 - 1219
[28] A Cost-effectiveness Analysis of Adding Cetuximab to the First-line Treatment of Metastatic Colorectal Carcinoma in Iran; Considering Genetic Screening for Precision Medicine
Yousefi, Nazila
Salimi, Alireza
Mohammadnezhad, Ghader
Taheri, Saeed
Peiravian, Farzad
JOURNAL OF GASTROINTESTINAL CANCER, 2023, 54 (04) : 1212 - 1219
[29] Effectiveness and Safety of Cetuximab as First-line Treatment in the Elderly with Metastatic Colorectal Cancer from the EREBUS Cohort
Fourrier-Reglat, Annie
Noize, Pernelle
Rouyer, Magali
Smith, Denis
Francois, Eric
Monnereau, Alain
Balestra, Aurelie
Jove, Jeremy
Lassalle, Regis
Moore, Nicholas
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2015, 24 : 310 - 310
[30] COST-EFFECTIVENESS ANALYSIS OF CETUXIMAB AND PANITUMUMAB FOR FIRST LINE TREATMENT OF METASTATIC COLORECTAL CANCER (MCRC) IN WT RAS PATIENTS IN SPAIN
Suarez, J.
VALUE IN HEALTH, 2015, 18 (07) : A460 - A460

← 1 2 3 4 5 →